[
    {
        "id": 2273,
        "drug_name": "ARISTADA INITIO (aripiprazole lauroxil)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Schizophrenia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-02",
        "link": "http:\/\/investor.alkermes.com\/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2356744",
        "note": "FDA approval announced July 2, 2018.",
        "company_entity_id": 31,
        "company_ticker": "ALKS",
        "company_name": "Alkermes plc",
        "company_price": "28.4700",
        "company_change": -0.13,
        "company_percent_change": -0.44999999999999996,
        "company_optionable": 1,
        "company_number_of_shares": 167076133,
        "price_change_sparkline": [
            [
                27.05,
                1706677200
            ],
            [
                26.94,
                1706763600
            ],
            [
                26.74,
                1706850000
            ],
            [
                26.4,
                1707109200
            ],
            [
                27.04,
                1707195600
            ],
            [
                26.7,
                1707282000
            ],
            [
                26.77,
                1707368400
            ],
            [
                27.32,
                1707454800
            ],
            [
                28.52,
                1707714000
            ],
            [
                27.23,
                1707800400
            ],
            [
                27.99,
                1707886800
            ],
            [
                32.56,
                1707973200
            ],
            [
                32.18,
                1708059600
            ],
            [
                30.39,
                1708405200
            ],
            [
                29.18,
                1708491600
            ],
            [
                28.91,
                1708578000
            ],
            [
                29.57,
                1708664400
            ],
            [
                30.04,
                1708923600
            ],
            [
                29.7,
                1709010000
            ],
            [
                29.8,
                1709096400
            ],
            [
                29.69,
                1709182800
            ],
            [
                30.24,
                1709269200
            ],
            [
                29.92,
                1709528400
            ],
            [
                29.76,
                1709614800
            ],
            [
                28.94,
                1709701200
            ],
            [
                29.45,
                1709787600
            ],
            [
                29.25,
                1709874000
            ],
            [
                28.6,
                1710129600
            ],
            [
                28.47,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4446,
        "drug_name": "OPDIVO (nivolumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-11",
        "link": "https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/bristol-myers-squibbs-opdivo-nivolumab-low-dose-yervoy-ipilimu",
        "note": "Approval announced July 11, 2018.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4499,
        "drug_name": "TPOXX",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Smallpox",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-13",
        "link": "http:\/\/investor.siga.com\/news-releases\/news-release-details\/us-food-and-drug-administration-approves-siga-technologies",
        "note": "FDA approval announced July 13, 2018.",
        "company_entity_id": 526,
        "company_ticker": "SIGA",
        "company_name": "SIGA Technologies Inc.",
        "company_price": "5.3200",
        "company_change": 0.43,
        "company_percent_change": 8.79,
        "company_optionable": 1,
        "company_number_of_shares": 71091616,
        "price_change_sparkline": [
            [
                4.88,
                1706677200
            ],
            [
                4.82,
                1706763600
            ],
            [
                4.66,
                1706850000
            ],
            [
                4.51,
                1707109200
            ],
            [
                4.63,
                1707195600
            ],
            [
                4.55,
                1707282000
            ],
            [
                4.64,
                1707368400
            ],
            [
                4.9,
                1707454800
            ],
            [
                5.09,
                1707714000
            ],
            [
                4.82,
                1707800400
            ],
            [
                5.01,
                1707886800
            ],
            [
                5.15,
                1707973200
            ],
            [
                5.15,
                1708059600
            ],
            [
                5.07,
                1708405200
            ],
            [
                5.19,
                1708491600
            ],
            [
                5.14,
                1708578000
            ],
            [
                5.32,
                1708664400
            ],
            [
                5.22,
                1708923600
            ],
            [
                5.37,
                1709010000
            ],
            [
                5.33,
                1709096400
            ],
            [
                5.21,
                1709182800
            ],
            [
                5.21,
                1709269200
            ],
            [
                5.09,
                1709528400
            ],
            [
                4.96,
                1709614800
            ],
            [
                5.02,
                1709701200
            ],
            [
                4.99,
                1709787600
            ],
            [
                4.86,
                1709874000
            ],
            [
                4.89,
                1710129600
            ],
            [
                5.32,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2810,
        "drug_name": "XTANDI (Enzalutamide) - (PROSPER)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-metastatic high risk hormone-sensitive prostate cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-13",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20180713005429\/en\/U.S.-FDA-Approves-XTANDI%C2%AE-enzalutamide-Treatment-Men",
        "note": "FDA approval announced July 13, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2356,
        "drug_name": "D\/C\/F\/TAF",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-18",
        "link": "https:\/\/seekingalpha.com\/pr\/17218654-janssen-announces-u-s-fda-approval-symtuza-d-c-f-taf-first-complete-darunavir-based-single",
        "note": "FDA Approval announced July 17, 2018.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3057,
        "drug_name": "TIBSOVO (ivosidenib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "IDH1m Relapsed\/Refractory AML - cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-20",
        "link": "https:\/\/agiospharmaceuticalsinc.gcs-web.com\/news-releases\/news-release-details\/fda-grants-approval-tibsovor-first-oral-targeted-therapy-adult",
        "note": "FDA Approval announced July 20, 2018.",
        "company_entity_id": 23,
        "company_ticker": "AGIO",
        "company_name": "Agios Pharmaceuticals Inc.",
        "company_price": "30.2900",
        "company_change": -0.51,
        "company_percent_change": -1.66,
        "company_optionable": 1,
        "company_number_of_shares": 56194847,
        "price_change_sparkline": [
            [
                22.62,
                1706677200
            ],
            [
                22.96,
                1706763600
            ],
            [
                23.09,
                1706850000
            ],
            [
                23.73,
                1707109200
            ],
            [
                24.15,
                1707195600
            ],
            [
                23.69,
                1707282000
            ],
            [
                24.18,
                1707368400
            ],
            [
                25.14,
                1707454800
            ],
            [
                25.88,
                1707714000
            ],
            [
                25.15,
                1707800400
            ],
            [
                25.9,
                1707886800
            ],
            [
                26.8,
                1707973200
            ],
            [
                26.51,
                1708059600
            ],
            [
                27.1,
                1708405200
            ],
            [
                26.8,
                1708491600
            ],
            [
                29.78,
                1708578000
            ],
            [
                32.99,
                1708664400
            ],
            [
                32.87,
                1708923600
            ],
            [
                34.81,
                1709010000
            ],
            [
                33.67,
                1709096400
            ],
            [
                32.32,
                1709182800
            ],
            [
                32.27,
                1709269200
            ],
            [
                32.17,
                1709528400
            ],
            [
                31.37,
                1709614800
            ],
            [
                31.79,
                1709701200
            ],
            [
                31.37,
                1709787600
            ],
            [
                31.29,
                1709874000
            ],
            [
                30.8,
                1710129600
            ],
            [
                30.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2261,
        "drug_name": "KRINTAFEL (Tafenoquine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Malaria",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-23",
        "link": "https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria\/",
        "note": "FDA Approval announced July 23, 2018.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4014,
        "drug_name": "ORILISSA (Elagolix)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Endometriosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-24",
        "link": "https:\/\/news.abbvie.com\/news\/abbvie-receives-us-fda-approval-orilissa-elagolix-for-management-moderate-to-severe-pain-associated-with-endometriosis.htm?view_id=822",
        "note": "FDA approval announced July 24, 2018.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4014,
        "drug_name": "ORILISSA (Elagolix)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Endometriosis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-24",
        "link": "https:\/\/news.abbvie.com\/news\/abbvie-receives-us-fda-approval-orilissa-elagolix-for-management-moderate-to-severe-pain-associated-with-endometriosis.htm?view_id=822",
        "note": "FDA approval announced July 24, 2018.",
        "company_entity_id": 205,
        "company_ticker": "NBIX",
        "company_name": "Neurocrine Biosciences Inc.",
        "company_price": "137.7400",
        "company_change": -0.87,
        "company_percent_change": -0.63,
        "company_optionable": 1,
        "company_number_of_shares": 99507490,
        "price_change_sparkline": [
            [
                139.77,
                1706677200
            ],
            [
                142.45,
                1706763600
            ],
            [
                141.74,
                1706850000
            ],
            [
                141.66,
                1707109200
            ],
            [
                142.96,
                1707195600
            ],
            [
                136.29,
                1707282000
            ],
            [
                134.42,
                1707368400
            ],
            [
                132.3,
                1707454800
            ],
            [
                130.43,
                1707714000
            ],
            [
                133.84,
                1707800400
            ],
            [
                131.77,
                1707886800
            ],
            [
                134,
                1707973200
            ],
            [
                132.31,
                1708059600
            ],
            [
                132.65,
                1708405200
            ],
            [
                130.65,
                1708491600
            ],
            [
                133.37,
                1708578000
            ],
            [
                134.18,
                1708664400
            ],
            [
                135.58,
                1708923600
            ],
            [
                136.03,
                1709010000
            ],
            [
                134.66,
                1709096400
            ],
            [
                130.4,
                1709182800
            ],
            [
                131.3,
                1709269200
            ],
            [
                133.12,
                1709528400
            ],
            [
                133.67,
                1709614800
            ],
            [
                132.25,
                1709701200
            ],
            [
                135.33,
                1709787600
            ],
            [
                139.22,
                1709874000
            ],
            [
                138.61,
                1710129600
            ],
            [
                137.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2250,
        "drug_name": "RBP-7000",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Schizophrenia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-27",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/fda-approves-perseris-risperidone-for-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-in-adults-300688082.html",
        "note": "FDA Approval announced July 27, 2018.",
        "company_entity_id": 119,
        "company_ticker": "DRRX",
        "company_name": "DURECT Corporation",
        "company_price": "1.1500",
        "company_change": 0.14,
        "company_percent_change": 13.86,
        "company_optionable": 1,
        "company_number_of_shares": 29828891,
        "price_change_sparkline": [
            [
                0.8121,
                1706677200
            ],
            [
                0.85,
                1706763600
            ],
            [
                0.849,
                1706850000
            ],
            [
                0.7824,
                1707109200
            ],
            [
                0.7566,
                1707195600
            ],
            [
                0.706,
                1707282000
            ],
            [
                0.756,
                1707368400
            ],
            [
                0.77,
                1707454800
            ],
            [
                0.85,
                1707714000
            ],
            [
                0.84,
                1707800400
            ],
            [
                0.945,
                1707886800
            ],
            [
                1.06,
                1707973200
            ],
            [
                1.04,
                1708059600
            ],
            [
                0.9694,
                1708405200
            ],
            [
                0.8801,
                1708491600
            ],
            [
                0.962,
                1708578000
            ],
            [
                0.98,
                1708664400
            ],
            [
                0.9567,
                1708923600
            ],
            [
                0.9951,
                1709010000
            ],
            [
                0.98,
                1709096400
            ],
            [
                1,
                1709182800
            ],
            [
                0.9813,
                1709269200
            ],
            [
                1.02,
                1709528400
            ],
            [
                0.97,
                1709614800
            ],
            [
                0.9777,
                1709701200
            ],
            [
                0.98,
                1709787600
            ],
            [
                1.01,
                1709874000
            ],
            [
                1.01,
                1710129600
            ],
            [
                1.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3716,
        "drug_name": "AZEDRA (iobenguane I 131)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Pheochromocytoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-07-30",
        "link": "https:\/\/progenicsgc.gcs-web.com\/news-releases\/news-release-details\/progenics-pharmaceuticals-announces-fda-approval-azedrar",
        "note": "FDA approval announced July 30, 2018.",
        "company_entity_id": 187,
        "company_ticker": "LNTH",
        "company_name": "Lantheus Holdings Inc.",
        "company_price": "60.8800",
        "company_change": -1.84,
        "company_percent_change": -2.93,
        "company_optionable": 1,
        "company_number_of_shares": 68525556,
        "price_change_sparkline": [
            [
                51.93,
                1706677200
            ],
            [
                53.01,
                1706763600
            ],
            [
                54,
                1706850000
            ],
            [
                54.06,
                1707109200
            ],
            [
                54.99,
                1707195600
            ],
            [
                54.6,
                1707282000
            ],
            [
                55.56,
                1707368400
            ],
            [
                56.14,
                1707454800
            ],
            [
                56.55,
                1707714000
            ],
            [
                54.89,
                1707800400
            ],
            [
                56.37,
                1707886800
            ],
            [
                57.75,
                1707973200
            ],
            [
                57.46,
                1708059600
            ],
            [
                56.83,
                1708405200
            ],
            [
                56.71,
                1708491600
            ],
            [
                65.05,
                1708578000
            ],
            [
                66.27,
                1708664400
            ],
            [
                68.14,
                1708923600
            ],
            [
                68.26,
                1709010000
            ],
            [
                65.37,
                1709096400
            ],
            [
                65.38,
                1709182800
            ],
            [
                64.64,
                1709269200
            ],
            [
                65.36,
                1709528400
            ],
            [
                64.44,
                1709614800
            ],
            [
                61.97,
                1709701200
            ],
            [
                62.59,
                1709787600
            ],
            [
                62.52,
                1709874000
            ],
            [
                62.72,
                1710129600
            ],
            [
                60.88,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5048,
        "drug_name": "ANNOVERA (Segesterone Acetate\/ Ethinyl Estradiol)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Contraception",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-10",
        "link": "http:\/\/ir.therapeuticsmd.com\/news-releases\/news-release-details\/therapeuticsmd-announces-fda-approval-annoveratm-segesterone",
        "note": "FDA Approval announced August 10, 2018.",
        "company_entity_id": 327,
        "company_ticker": "TXMD",
        "company_name": "TherapeuticsMD Inc.",
        "company_price": "2.3850",
        "company_change": 0.16,
        "company_percent_change": 6.95,
        "company_optionable": 1,
        "company_number_of_shares": 10575240,
        "price_change_sparkline": [
            [
                2.26,
                1706677200
            ],
            [
                2.26,
                1706763600
            ],
            [
                2.27,
                1706850000
            ],
            [
                2.29,
                1707109200
            ],
            [
                2.29,
                1707195600
            ],
            [
                2.27,
                1707282000
            ],
            [
                2.29,
                1707368400
            ],
            [
                2.29,
                1707454800
            ],
            [
                2.25,
                1707714000
            ],
            [
                2.24,
                1707800400
            ],
            [
                2.29,
                1707886800
            ],
            [
                2.24,
                1707973200
            ],
            [
                2.26,
                1708059600
            ],
            [
                2.27,
                1708405200
            ],
            [
                2.26,
                1708491600
            ],
            [
                2.26,
                1708578000
            ],
            [
                2.25,
                1708664400
            ],
            [
                2.29,
                1708923600
            ],
            [
                2.35,
                1709010000
            ],
            [
                2.37,
                1709096400
            ],
            [
                2.4,
                1709182800
            ],
            [
                2.54,
                1709269200
            ],
            [
                2.635,
                1709528400
            ],
            [
                2.69,
                1709614800
            ],
            [
                2.45,
                1709701200
            ],
            [
                2.29,
                1709787600
            ],
            [
                2.33,
                1709874000
            ],
            [
                2.23,
                1710129600
            ],
            [
                2.385,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3909,
        "drug_name": "ONPATTRO (patisiran)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-10",
        "link": "http:\/\/investors.alnylam.com\/news-releases\/news-release-details\/alnylam-announces-first-ever-fda-approval-rnai-therapeutic",
        "note": "FDA Approval announced August 10, 2018.",
        "company_entity_id": 32,
        "company_ticker": "ALNY",
        "company_name": "Alnylam Pharmaceuticals Inc.",
        "company_price": "146.6500",
        "company_change": -2.45,
        "company_percent_change": -1.6400000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 125945793,
        "price_change_sparkline": [
            [
                172.91,
                1706677200
            ],
            [
                174.92,
                1706763600
            ],
            [
                173.06,
                1706850000
            ],
            [
                170.7,
                1707109200
            ],
            [
                172.18,
                1707195600
            ],
            [
                168.6,
                1707282000
            ],
            [
                169.5,
                1707368400
            ],
            [
                170.03,
                1707454800
            ],
            [
                169.34,
                1707714000
            ],
            [
                162,
                1707800400
            ],
            [
                164.15,
                1707886800
            ],
            [
                147.43,
                1707973200
            ],
            [
                147,
                1708059600
            ],
            [
                149.69,
                1708405200
            ],
            [
                154.74,
                1708491600
            ],
            [
                162.81,
                1708578000
            ],
            [
                157.65,
                1708664400
            ],
            [
                158.66,
                1708923600
            ],
            [
                159,
                1709010000
            ],
            [
                155.23,
                1709096400
            ],
            [
                151.09,
                1709182800
            ],
            [
                152.61,
                1709269200
            ],
            [
                150.04,
                1709528400
            ],
            [
                149.68,
                1709614800
            ],
            [
                149.66,
                1709701200
            ],
            [
                149.86,
                1709787600
            ],
            [
                149.82,
                1709874000
            ],
            [
                149.1,
                1710129600
            ],
            [
                146.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3909,
        "drug_name": "ONPATTRO (patisiran)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-10",
        "link": "http:\/\/investors.alnylam.com\/news-releases\/news-release-details\/alnylam-announces-first-ever-fda-approval-rnai-therapeutic",
        "note": "FDA Approval announced August 10, 2018.",
        "company_entity_id": 389,
        "company_ticker": "SNY",
        "company_name": "Sanofi",
        "company_price": "48.4600",
        "company_change": 0.11,
        "company_percent_change": 0.23,
        "company_optionable": 1,
        "company_number_of_shares": 2529599938,
        "price_change_sparkline": [
            [
                49.9,
                1706677200
            ],
            [
                48.41,
                1706763600
            ],
            [
                47.23,
                1706850000
            ],
            [
                46.95,
                1707109200
            ],
            [
                47.06,
                1707195600
            ],
            [
                46.92,
                1707282000
            ],
            [
                46.56,
                1707368400
            ],
            [
                46.5,
                1707454800
            ],
            [
                46.34,
                1707714000
            ],
            [
                45.75,
                1707800400
            ],
            [
                45.8,
                1707886800
            ],
            [
                46.39,
                1707973200
            ],
            [
                46.18,
                1708059600
            ],
            [
                46.85,
                1708405200
            ],
            [
                47.92,
                1708491600
            ],
            [
                47.8,
                1708578000
            ],
            [
                48.77,
                1708664400
            ],
            [
                48.2,
                1708923600
            ],
            [
                48.21,
                1709010000
            ],
            [
                48,
                1709096400
            ],
            [
                47.85,
                1709182800
            ],
            [
                47.29,
                1709269200
            ],
            [
                47.15,
                1709528400
            ],
            [
                47.5,
                1709614800
            ],
            [
                47.68,
                1709701200
            ],
            [
                48.06,
                1709787600
            ],
            [
                48.25,
                1709874000
            ],
            [
                48.35,
                1710129600
            ],
            [
                48.46,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3532,
        "drug_name": "GALAFOLD (Migalastat)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Fabry Disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-10",
        "link": "http:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/fda-approves-galafoldtm-migalastat-treatment-certain-adult",
        "note": "FDA Approval announced August 10, 2018.",
        "company_entity_id": 144,
        "company_ticker": "FOLD",
        "company_name": "Amicus Therapeutics Inc.",
        "company_price": "11.7900",
        "company_change": -0.33999999999999997,
        "company_percent_change": -2.8,
        "company_optionable": 1,
        "company_number_of_shares": 295382614,
        "price_change_sparkline": [
            [
                12.43,
                1706677200
            ],
            [
                12.67,
                1706763600
            ],
            [
                12.44,
                1706850000
            ],
            [
                12.7,
                1707109200
            ],
            [
                12.98,
                1707195600
            ],
            [
                13,
                1707282000
            ],
            [
                13.33,
                1707368400
            ],
            [
                13.55,
                1707454800
            ],
            [
                13.77,
                1707714000
            ],
            [
                12.8,
                1707800400
            ],
            [
                13.18,
                1707886800
            ],
            [
                14,
                1707973200
            ],
            [
                13.76,
                1708059600
            ],
            [
                13.7,
                1708405200
            ],
            [
                13.56,
                1708491600
            ],
            [
                13.4,
                1708578000
            ],
            [
                13.53,
                1708664400
            ],
            [
                13.78,
                1708923600
            ],
            [
                13.85,
                1709010000
            ],
            [
                12.95,
                1709096400
            ],
            [
                12.82,
                1709182800
            ],
            [
                13.29,
                1709269200
            ],
            [
                13.46,
                1709528400
            ],
            [
                13.35,
                1709614800
            ],
            [
                12.6,
                1709701200
            ],
            [
                12.29,
                1709787600
            ],
            [
                12.3,
                1709874000
            ],
            [
                12.13,
                1710129600
            ],
            [
                11.79,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4654,
        "drug_name": "OPDIVO (nivolumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Small cell lung cancer (SCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-17",
        "link": "https:\/\/news.bms.com\/press-release\/corporatefinancial-news\/us-food-and-drug-administration-approves-opdivo-nivolumab-firs",
        "note": "FDA approval announced August 17, 2018.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9953,
        "drug_name": "Kyslecel",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Acute pancreatitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-22",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/koligo-introduces-kyslecel-autologous-cell-therapy-product-300701159.html",
        "note": "Approved August 22, 2018.",
        "company_entity_id": 1543,
        "company_ticker": "ORGS",
        "company_name": "Orgenesis Inc.",
        "company_price": "0.8600",
        "company_change": 0.04,
        "company_percent_change": 4.67,
        "company_optionable": 1,
        "company_number_of_shares": 31877063,
        "price_change_sparkline": [
            [
                0.314,
                1706677200
            ],
            [
                0.328,
                1706763600
            ],
            [
                0.3111,
                1706850000
            ],
            [
                0.299,
                1707109200
            ],
            [
                0.312627,
                1707195600
            ],
            [
                0.3001,
                1707282000
            ],
            [
                0.301,
                1707368400
            ],
            [
                0.2997,
                1707454800
            ],
            [
                0.299,
                1707714000
            ],
            [
                0.296,
                1707800400
            ],
            [
                0.341,
                1707886800
            ],
            [
                0.48,
                1707973200
            ],
            [
                0.4,
                1708059600
            ],
            [
                0.409,
                1708405200
            ],
            [
                0.47,
                1708491600
            ],
            [
                0.4815,
                1708578000
            ],
            [
                0.59,
                1708664400
            ],
            [
                0.63,
                1708923600
            ],
            [
                0.6001,
                1709010000
            ],
            [
                0.623,
                1709096400
            ],
            [
                0.6402,
                1709182800
            ],
            [
                0.6809,
                1709269200
            ],
            [
                0.767,
                1709528400
            ],
            [
                0.8217,
                1709614800
            ],
            [
                0.831,
                1709701200
            ],
            [
                0.839,
                1709787600
            ],
            [
                0.8574,
                1709874000
            ],
            [
                0.82,
                1710129600
            ],
            [
                0.86,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2362,
        "drug_name": "INVELTYS",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Post\u2011operative inflammation and pain following cataract surgery",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-23",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20180823005645\/en\/Kala-Pharmaceuticals-Announces-FDA-Approval-INVELTYS%E2%84%A2-Treatment",
        "note": "FDA approval announced August 23, 2018.",
        "company_entity_id": 447,
        "company_ticker": "KALA",
        "company_name": "KALA BIO Inc.",
        "company_price": "7.5700",
        "company_change": -0.25,
        "company_percent_change": -3.2,
        "company_optionable": 0,
        "company_number_of_shares": 2693116,
        "price_change_sparkline": [
            [
                6.95,
                1706677200
            ],
            [
                6.88,
                1706763600
            ],
            [
                6.96,
                1706850000
            ],
            [
                6.97,
                1707109200
            ],
            [
                7.0099,
                1707195600
            ],
            [
                6.98,
                1707282000
            ],
            [
                6.94,
                1707368400
            ],
            [
                7.37,
                1707454800
            ],
            [
                7.18,
                1707714000
            ],
            [
                6.99,
                1707800400
            ],
            [
                6.87,
                1707886800
            ],
            [
                7.18,
                1707973200
            ],
            [
                7.09,
                1708059600
            ],
            [
                7.17,
                1708405200
            ],
            [
                7.14,
                1708491600
            ],
            [
                7.9999,
                1708578000
            ],
            [
                7.06,
                1708664400
            ],
            [
                7.2336,
                1708923600
            ],
            [
                7.15,
                1709010000
            ],
            [
                7.185,
                1709096400
            ],
            [
                7.18,
                1709182800
            ],
            [
                7.33,
                1709269200
            ],
            [
                7.66,
                1709528400
            ],
            [
                7.475,
                1709614800
            ],
            [
                7.49,
                1709701200
            ],
            [
                7.33,
                1709787600
            ],
            [
                7.5,
                1709874000
            ],
            [
                7.82,
                1710129600
            ],
            [
                7.57,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2777,
        "drug_name": "ALTRENO1 (IDP-121)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acne",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-24",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/ortho-dermatologics-receives-fda-approval-for-altreno-tretinoin-0-05-lotion-for-acne-300702073.html",
        "note": "FDA Approval announced August 24, 2018.",
        "company_entity_id": 574,
        "company_ticker": "BHC",
        "company_name": "Bausch Health Companies Inc.",
        "company_price": "9.1900",
        "company_change": 0.07,
        "company_percent_change": 0.77,
        "company_optionable": 1,
        "company_number_of_shares": 365411953,
        "price_change_sparkline": [
            [
                7.85,
                1706677200
            ],
            [
                7.98,
                1706763600
            ],
            [
                7.92,
                1706850000
            ],
            [
                7.77,
                1707109200
            ],
            [
                8.13,
                1707195600
            ],
            [
                8.12,
                1707282000
            ],
            [
                8.13,
                1707368400
            ],
            [
                8.21,
                1707454800
            ],
            [
                8.38,
                1707714000
            ],
            [
                8.41,
                1707800400
            ],
            [
                8.43,
                1707886800
            ],
            [
                8.49,
                1707973200
            ],
            [
                8.51,
                1708059600
            ],
            [
                8.6,
                1708405200
            ],
            [
                8.67,
                1708491600
            ],
            [
                9.3,
                1708578000
            ],
            [
                9.18,
                1708664400
            ],
            [
                8.99,
                1708923600
            ],
            [
                9.18,
                1709010000
            ],
            [
                9.2,
                1709096400
            ],
            [
                9.39,
                1709182800
            ],
            [
                9.89,
                1709269200
            ],
            [
                9.58,
                1709528400
            ],
            [
                9.56,
                1709614800
            ],
            [
                9.23,
                1709701200
            ],
            [
                9.28,
                1709787600
            ],
            [
                9.23,
                1709874000
            ],
            [
                9.12,
                1710129600
            ],
            [
                9.19,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4931,
        "drug_name": "IMBRUVICA (ibrutinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Waldenstr\u00f6m\u2019s Macroglobulinemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-27",
        "link": "https:\/\/news.abbvie.com\/news\/abbvie-announces-imbruvica-ibrutinib-plus-rituximab-approval-by-us-fda-as-first-chemotherapy-free-combination-treatment-in-adults-with-waldenstrms-macroglobulinemia-rare-type-blood-cancer.htm?view_id=822",
        "note": "FDA approval announced August 27, 2018.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4931,
        "drug_name": "IMBRUVICA (ibrutinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Waldenstr\u00f6m\u2019s Macroglobulinemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-27",
        "link": "https:\/\/news.abbvie.com\/news\/abbvie-announces-imbruvica-ibrutinib-plus-rituximab-approval-by-us-fda-as-first-chemotherapy-free-combination-treatment-in-adults-with-waldenstrms-macroglobulinemia-rare-type-blood-cancer.htm?view_id=822",
        "note": "FDA approval announced August 27, 2018.",
        "company_entity_id": 380,
        "company_ticker": "JNJ",
        "company_name": "Johnson & Johnson",
        "company_price": "162.7400",
        "company_change": 1.51,
        "company_percent_change": 0.94,
        "company_optionable": 1,
        "company_number_of_shares": 2408767228,
        "price_change_sparkline": [
            [
                157.701248890579,
                1706677200
            ],
            [
                157.165322682896,
                1706763600
            ],
            [
                155.428524787625,
                1706850000
            ],
            [
                154.6246354761,
                1707109200
            ],
            [
                156.867585900849,
                1707195600
            ],
            [
                156.788189425637,
                1707282000
            ],
            [
                155.220109040193,
                1707368400
            ],
            [
                155.577393178648,
                1707454800
            ],
            [
                156.659170153417,
                1707714000
            ],
            [
                155.289580956004,
                1707800400
            ],
            [
                154.565088119691,
                1707886800
            ],
            [
                156.728642069228,
                1707973200
            ],
            [
                156.55,
                1708059600
            ],
            [
                157.86,
                1708405200
            ],
            [
                158.68,
                1708491600
            ],
            [
                160.45,
                1708578000
            ],
            [
                161.84,
                1708664400
            ],
            [
                160.79,
                1708923600
            ],
            [
                160.98,
                1709010000
            ],
            [
                161.55,
                1709096400
            ],
            [
                161.38,
                1709182800
            ],
            [
                162.12,
                1709269200
            ],
            [
                159.84,
                1709528400
            ],
            [
                159.97,
                1709614800
            ],
            [
                159.34,
                1709701200
            ],
            [
                158.87,
                1709787600
            ],
            [
                159.52,
                1709874000
            ],
            [
                161.23,
                1710129600
            ],
            [
                162.74,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3972,
        "drug_name": "XERAVA (eravacycline)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "cIAI (complicated intra-abdominal infections)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-27",
        "link": "https:\/\/ir.tphase.com\/news-releases\/news-release-details\/tetraphase-pharmaceuticals-announces-fda-approval-xeravatm",
        "note": "FDA approval announced August 27, 2018.",
        "company_entity_id": 391,
        "company_ticker": "INVA",
        "company_name": "Innoviva Inc.",
        "company_price": "14.8200",
        "company_change": 0.03,
        "company_percent_change": 0.2,
        "company_optionable": 1,
        "company_number_of_shares": 63227333,
        "price_change_sparkline": [
            [
                16.2,
                1706677200
            ],
            [
                16.29,
                1706763600
            ],
            [
                15.9,
                1706850000
            ],
            [
                15.82,
                1707109200
            ],
            [
                15.89,
                1707195600
            ],
            [
                15.53,
                1707282000
            ],
            [
                15.6,
                1707368400
            ],
            [
                15.69,
                1707454800
            ],
            [
                15.71,
                1707714000
            ],
            [
                15.48,
                1707800400
            ],
            [
                15.8,
                1707886800
            ],
            [
                16,
                1707973200
            ],
            [
                15.86,
                1708059600
            ],
            [
                15.8,
                1708405200
            ],
            [
                15.67,
                1708491600
            ],
            [
                15.48,
                1708578000
            ],
            [
                15.48,
                1708664400
            ],
            [
                15.52,
                1708923600
            ],
            [
                15.37,
                1709010000
            ],
            [
                15.35,
                1709096400
            ],
            [
                15.28,
                1709182800
            ],
            [
                15.24,
                1709269200
            ],
            [
                15.26,
                1709528400
            ],
            [
                14.88,
                1709614800
            ],
            [
                15.18,
                1709701200
            ],
            [
                15.08,
                1709787600
            ],
            [
                14.84,
                1709874000
            ],
            [
                14.79,
                1710129600
            ],
            [
                14.82,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5080,
        "drug_name": "Sympazan",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Lennox-Gastaut Syndrome",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-08-31",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/aquestive-therapeutics-announces-tentative-fda-approval-for-sympazan-clobazam-oral-film-300705498.html",
        "note": "Tentative approval announced August 31, 2018.",
        "company_entity_id": 582,
        "company_ticker": "AQST",
        "company_name": "Aquestive Therapeutics Inc.",
        "company_price": "5.1000",
        "company_change": 0.16,
        "company_percent_change": 3.24,
        "company_optionable": 1,
        "company_number_of_shares": 73301201,
        "price_change_sparkline": [
            [
                2.39,
                1706677200
            ],
            [
                2.67,
                1706763600
            ],
            [
                2.63,
                1706850000
            ],
            [
                2.7,
                1707109200
            ],
            [
                2.79,
                1707195600
            ],
            [
                2.64,
                1707282000
            ],
            [
                2.68,
                1707368400
            ],
            [
                2.75,
                1707454800
            ],
            [
                2.77,
                1707714000
            ],
            [
                2.65,
                1707800400
            ],
            [
                2.68,
                1707886800
            ],
            [
                2.72,
                1707973200
            ],
            [
                2.695,
                1708059600
            ],
            [
                2.65,
                1708405200
            ],
            [
                2.51,
                1708491600
            ],
            [
                2.63,
                1708578000
            ],
            [
                2.57,
                1708664400
            ],
            [
                2.85,
                1708923600
            ],
            [
                3.2,
                1709010000
            ],
            [
                3.65,
                1709096400
            ],
            [
                3.67,
                1709182800
            ],
            [
                4.24,
                1709269200
            ],
            [
                4.18,
                1709528400
            ],
            [
                4.19,
                1709614800
            ],
            [
                5.03,
                1709701200
            ],
            [
                5.68,
                1709787600
            ],
            [
                4.88,
                1709874000
            ],
            [
                4.94,
                1710129600
            ],
            [
                5.1,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2970,
        "drug_name": "LUMOXITI (moxetumomab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Cancer - leukaemia",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-09-13",
        "link": "https:\/\/bit.ly\/2OeGCgC",
        "note": "Approval announced September 13, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    }
]